VTGN - VistaGen Therapeutics EPS misses by $0.02 beats on revenue February, 11 2021 04:54 PM VistaGen Therapeutics Inc. VistaGen Therapeutics (VTGN): Q3 GAAP EPS of -$0.07 misses by $0.02.Revenue of $0.31M beats by $0.14M.Press Release For further details see: VistaGen Therapeutics EPS misses by $0.02, beats on revenue